<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006321" GROUP_ID="IBD" ID="060106110814382588" MERGED_FROM="" MODIFIED="2010-04-23 20:30:43 +0200" MODIFIED_BY="John MacDonald" REVIEW_NO="123" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2010-04-23 20:30:43 +0200" MODIFIED_BY="John MacDonald">
<TITLE MODIFIED="2008-12-15 11:14:07 -0500" MODIFIED_BY="John K MacDonald">Human growth hormone and glutamine for patients with short bowel syndrome</TITLE>
<CONTACT MODIFIED="2010-04-23 20:30:43 +0200" MODIFIED_BY="John MacDonald"><PERSON ID="E4E650F182E26AA2009C393DCC4478FD" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Paul</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Wales</LAST_NAME><POSITION>Paediatric Surgeon</POSITION><EMAIL_1>paul.wales@sickkids.ca</EMAIL_1><ADDRESS><DEPARTMENT>Division of General Surgery and Group for Improvement of Intestinal Function and Treatment (GIFT)</DEPARTMENT><ORGANISATION>The Hospital for Sick Children</ORGANISATION><ADDRESS_1>Rm 1526, 555 University Ave</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1X8</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416 813 7654 ext 1490</PHONE_1><FAX_1>+1 416 813 7477</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-04-23 20:30:43 +0200" MODIFIED_BY="John MacDonald"><PERSON ID="E4E650F182E26AA2009C393DCC4478FD" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Paul</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Wales</LAST_NAME><POSITION>Paediatric Surgeon</POSITION><EMAIL_1>paul.wales@sickkids.ca</EMAIL_1><ADDRESS><DEPARTMENT>Division of General Surgery and Group for Improvement of Intestinal Function and Treatment (GIFT)</DEPARTMENT><ORGANISATION>The Hospital for Sick Children</ORGANISATION><ADDRESS_1>Rm 1526, 555 University Ave</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1X8</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416 813 7654 ext 1490</PHONE_1><FAX_1>+1 416 813 7477</FAX_1></ADDRESS></PERSON><PERSON ID="E4EF003282E26AA2009C393D2625C174" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ahmed</FIRST_NAME><LAST_NAME>Nasr</LAST_NAME><POSITION>General Surgery Resident</POSITION><EMAIL_1>ahmed.nasr@sickkids.ca</EMAIL_1><EMAIL_2>nasr@rogers.com</EMAIL_2><ADDRESS><DEPARTMENT>Division of General Surgery</DEPARTMENT><ORGANISATION>The Hospital for Sick Children</ORGANISATION><ADDRESS_1>555 University Ave</ADDRESS_1><ADDRESS_2>Room 1526</ADDRESS_2><CITY>Toronto</CITY><ZIP>M5G 1X8</ZIP><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416 813 7654 ext 1490</PHONE_1></ADDRESS></PERSON><PERSON ID="E5019F8082E26AA2009C393D1478FC15" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Nicole</FIRST_NAME><LAST_NAME>de Silva</LAST_NAME><POSITION>CNS-NP Neonatology/General Surgery</POSITION><EMAIL_1>nicole.desilva@sickkids.ca</EMAIL_1><ADDRESS><DEPARTMENT>Neonatology and Group for Improvement of Intestinal Function and Treatment (GIFT)</DEPARTMENT><ORGANISATION>The Hospital for Sick Children</ORGANISATION><ADDRESS_1>555 University Ave</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1X8</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416 813 6736</PHONE_1></ADDRESS></PERSON><PERSON ID="15351" ROLE="AUTHOR"><FIRST_NAME>Janet</FIRST_NAME><LAST_NAME>Yamada</LAST_NAME><POSITION>Nursing Research Program Coordinator</POSITION><EMAIL_1>janet.yamada@sickkids.ca</EMAIL_1><ADDRESS><DEPARTMENT>Nursing</DEPARTMENT><ORGANISATION>The Hospital for Sick Children</ORGANISATION><ADDRESS_1>555 University Avenue</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1X8</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>416-813-1088</PHONE_1><FAX_1>416-813-8273</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-04-13 11:28:04 -0400" MODIFIED_BY="John K MacDonald">
<UP_TO_DATE>
<DATE DAY="31" MONTH="12" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="12" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="4" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2010-04-13 11:30:10 -0400" MODIFIED_BY="John K MacDonald">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-04-13 11:30:10 -0400" MODIFIED_BY="John K MacDonald">
<DATE DAY="13" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-04-13 11:29:47 -0400" MODIFIED_BY="John K MacDonald"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Division of General Surgery. The Hospital for Sick Children</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-04-23 14:17:30 -0400" MODIFIED_BY="John K MacDonald">
<SUMMARY MODIFIED="2010-04-23 14:17:30 -0400" MODIFIED_BY="John K MacDonald">
<TITLE MODIFIED="2010-04-07 12:51:32 -0400" MODIFIED_BY="John K MacDonald">Human growth hormone and glutamine for patients with short bowel syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2010-04-23 14:17:30 -0400" MODIFIED_BY="John K MacDonald">
<P>Short bowel syndrome is a malabsorption disorder caused by the surgical removal of the small intestine, or by the complete dysfunction of a large segment of bowel. It is a challenging health problem to treat. Several small studies have assessed the benefit of providing drugs such as human growth hormone and glutamine in an attempt to improve intestinal function and wean intravenous nutrition (liquid food).  The results of this review of 5 small studies suggest that human growth hormone used with or without glutamine may provide short term benefit for patients with short bowel syndrome in terms of weight gain and intestinal absorption of nutrients. However the benefits of treatment do not continue after treatment is stopped. Common side effects of treatment include peripheral edema (swelling of tissues, usually in the lower limbs), and carpal tunnel syndrome (numbness and muscle weakness in the hand). Conclusive evidence is not available to recommend this treatment.  Further studies that evaluate human growth hormone treatment during the immediate phase of bowel adaptation are needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-04-23 14:16:11 -0400" MODIFIED_BY="John K MacDonald">
<ABS_BACKGROUND MODIFIED="2010-04-13 12:12:37 -0400" MODIFIED_BY="John K MacDonald">
<P>There has been clinical enthusiasm for treating short bowel patients with human recombinant growth hormone and/or glutamine in hopes of reducing parenteral nutrition dependency. It has been more than a decade since Byrne and colleagues reported enhanced absorption of nutrients, improved weight gain, and reduction in parenteral nutrition requirements with the administration of a combination of human growth hormone (HGH) and glutamine in patients with short bowel syndrome. Other studies have reported inconsistent results.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-04-13 11:30:38 -0400" MODIFIED_BY="John K MacDonald">
<P>The purpose of this systematic review was to evaluate the efficacy of growth hormone with or without glutamine supplementation for adult patients with short bowel syndrome.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-04-23 14:14:20 -0400" MODIFIED_BY="John K MacDonald">
<P>Electronic searches were performed to identify all publications describing randomised controlled trials of the use of human growth hormone with or without glutamine for the treatment of patients with short bowel syndrome.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-04-13 12:12:41 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomised controlled trials of human growth hormone with or without glutamine for patients with short bowel syndrome were considered for inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-04-13 12:12:44 -0400" MODIFIED_BY="John K MacDonald">
<P>Two authors independently extracted data from the published studies. The statistical analyses were performed using RevMan 5 software. Follmann's method was used for cross-over studies. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-04-13 12:12:50 -0400" MODIFIED_BY="John K MacDonald">
<P>Five studies were included in the review. Human growth hormone with or without glutamine appears to provide benefit in terms of increased weight (MD 1.66 Kg; 95% CI 0.69 to 2.63;P = 0.0008), lean body mass (MD 1.93 Kg; 95% CI 0.97 to 2.90; P = 0.0001) energy absorption (MD 4.42 Kcal; 95% CI 0.26 to 8.58; P = 0.04) and nitrogen absorption (MD 44.85 g; 95%CI 0.20 to 9.49; P = 0.04) for patients with short bowel syndrome. The single RCT that focused on parenteral nutrition (PN) requirements demonstrated decreased PN volume and calories and number of infusions in patients who received HGH with or without glutamine supplementation.  Only patients who received HGH with glutamine maintained statistically significant PN reductions at 3 month follow-up. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-04-23 14:16:11 -0400" MODIFIED_BY="John K MacDonald">
<P>The results suggest a positive effect of human growth hormone on weight gain and energy absorption. However, in the majority of trials, the effects are short-lived returning to baseline shortly after cessation of therapy. The temporary benefit calls into question the clinical utility of this treatment.  To date, the evidence is inconclusive to recommend this therapy.  Consideration should be made to studying patients during the active phase of intestinal adaptation rather than in the setting of chronic intestinal failure.  The role of HGH in paediatric short bowel syndrome remains unknown.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-04-13 12:36:16 -0400" MODIFIED_BY="John K MacDonald">
<BACKGROUND MODIFIED="2010-04-13 12:34:37 -0400" MODIFIED_BY="John K MacDonald">
<P>Patients who undergo extensive resection of the gastrointestinal tract may subsequently develop intestinal failure secondary to short-bowel syndrome. Intestinal failure occurs in the absence of minimum intestinal mass required for adequate digestion and absorption of nutrients leading to malnutrition and/or dehydration. Depending on the extent, degree, and location of the resection, patients may experience severe malabsorption of fluid, electrolytes, and other nutrients (<LINK REF="REF-Li_x002d_Ling-2001" TYPE="REFERENCE">Li-Ling 2001</LINK>). Many of these patients become dependent on long-term parenteral nutrition. Due to the potential complications, cost, and quality of life issues, alternative therapies to parenteral nutrition such as aggressive intestinal rehabilitation and small bowel transplantation have been developed (<LINK REF="REF-Thompson-1993" TYPE="REFERENCE">Thompson 1993</LINK>; <LINK REF="REF-Abu_x002d_Elmagd-1994" TYPE="REFERENCE">Abu-Elmagd 1994</LINK>).<BR/>
<BR/>Intestinal adaptation, first described by Flint (<LINK REF="REF-Flint-1912" TYPE="REFERENCE">Flint 1912</LINK>) is a process whereby the remnant bowel begins to compensate for the loss of the resected portion following small bowel resection. It is believed that this adaptive phase continues for 2 years in adults (<LINK REF="REF-Messing-1999" TYPE="REFERENCE">Messing 1999</LINK>;<LINK REF="REF-Nighttingale-1999" TYPE="REFERENCE">Nighttingale 1999</LINK>). The exact mechanism by which these alterations in bowel morphology and function occur is not known, but the process includes both structural and functional aspects (<LINK REF="REF-Nighttingale-1993" TYPE="REFERENCE">Nighttingale 1993</LINK>). During this process the bowel dilates and elongates and there is an increase in villus height, crypt depth, cell proliferation and enzyme activity. This results in enhanced fluid, electrolyte, and nutrient absorption as well as prolonged transit time (<LINK REF="REF-Flint-1912" TYPE="REFERENCE">Flint 1912</LINK>).<BR/>
<BR/>Intestinal adaptation occurs in response to enteral nutrition, intestinal secretions and hormonal factors. Trophic changes have been observed in animals when various growth factors such as growth hormone, insulin-like growth factor-1, glucagon-like peptide-2, specific nutrients such as glutamine, short-chain fatty acids, pancreatic-biliary secretions are supplemented (<LINK REF="REF-Rhoads-1991" TYPE="REFERENCE">Rhoads 1991</LINK>; <LINK REF="REF-Tamada-1993" TYPE="REFERENCE">Tamada 1993</LINK>; <LINK REF="REF-Souba-1985" TYPE="REFERENCE">Souba 1985</LINK>; <LINK REF="REF-Jacobs-1983" TYPE="REFERENCE">Jacobs 1983</LINK>; <LINK REF="REF-Gardemann-1992" TYPE="REFERENCE">Gardemann 1992</LINK>). Together these trophic stimuli allow the remnant bowel to adapt (hypertrophy). Attempts to increase the absorptive capacity of the remnant bowel have been made by promoting pharmacologic adaptation through the use of hormonal intestinal trophic factors (<LINK REF="REF-Lentze-1989" TYPE="REFERENCE">Lentze 1989</LINK>).</P>
<P>Byrne and colleagues first demonstrated, through an open label clinical trial and a case series (<LINK REF="STD-Byrne-1995a" TYPE="STUDY">Byrne 1995a</LINK>; <LINK REF="REF-Byrne-1995b" TYPE="REFERENCE">Byrne 1995b</LINK>), the benefit to intestinal adaptation by administering growth hormone and glutamine in ten patients with remnant small intestine who had been on long term parenteral nutrition. These results attracted much interest and in the following years several other trials were published. A few case series were published suggesting the benefit of both human growth hormone (HGH) and glutamine in patients with short bowel (<LINK REF="REF-Scheppach-1994" TYPE="REFERENCE">Scheppach 1994</LINK>; <LINK REF="REF-Inoue-1994" TYPE="REFERENCE">Inoue 1994</LINK>). However, controversy still surrounds the use of growth hormone and glutamine in these patients. The number of studies in this area is limited and the results are conflicting.</P>
<P>On the basis of previous animal studies, it appears that the combination of GH and glutamine has a synergistic effect on intestinal function (<LINK REF="REF-Gu-2001" TYPE="REFERENCE">Gu 2001</LINK>; <LINK REF="REF-Ziegler-1996" TYPE="REFERENCE">Ziegler 1996</LINK>). Glutamine is a required substrate for ornithine decarboxylase and an essential precursor for nucleotide biosynthesis. Certainly, there is no reason to suggest a negative or cancelling effect when glutamine is given with HGH. There appears to be no carry over effect using these drugs in a cross-over design, due to its confirmed short half life (<LINK REF="REF-Li_x002d_Ling-2001" TYPE="REFERENCE">Li-Ling 2001</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-04-13 11:34:37 -0400" MODIFIED_BY="John K MacDonald">
<P>The purpose of this systematic review was to evaluate the efficacy of growth hormone with or without glutamine supplementation for adult patients with short bowel syndrome.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-04-13 12:14:12 -0400" MODIFIED_BY="John K MacDonald">
<SELECTION_CRITERIA MODIFIED="2010-04-13 12:13:37 -0400" MODIFIED_BY="John K MacDonald">
<CRIT_STUDIES MODIFIED="2010-04-13 12:13:23 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomised controlled trials of human growth hormone with or without glutamine for patients with short bowel syndrome were considered for inclusion. Letters, editorials, commentaries, reviews and lectures that do not contain original research data and studies that used historical controls were excluded. For studies in which further data were required the authors were contacted for further information. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-04-13 12:13:27 -0400" MODIFIED_BY="John K MacDonald">
<P>Adult patients diagnosed with short bowel syndrome and dependent on parenteral nutrition support were considered for inclusion. Short bowel syndrome was defined as "reduction of functioning gut mass below the amount necessary for adequate digestion and absorption of nutrients".</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-04-13 12:13:28 -0400" MODIFIED_BY="John K MacDonald">
<P>Studies in which human recombinant growth hormone with or without glutamine were compared to placebo were considered for inclusion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-04-13 12:13:37 -0400" MODIFIED_BY="John K MacDonald">
<P>Studies were considered for inclusion if they reported on one or more of the following outcomes:</P>
<P>
<B>Primary outcome</B>: Change in body weight (Kg); and <BR/>
</P>
<P>
<B>Secondary outcomes</B>:<BR/>
</P>
<UL>
<LI>Change in lean body mass (LBM) in Kg (measured using Dual energy x ray or bioelectric impedance analysis);</LI>
<LI>Change in total energy absorption in Kcal (measured using bomb calorimetry or by subtracting the amount of energy excreted in stool output from that actually ingested);</LI>
<LI>Changes in fat, carbohydrate and nitrogen absorption in grams (measured as the difference between intake and fecal loss);</LI>
<LI>Change in serum level of insulin-like growth factor-1 (IGF-1) ng/mL (measured by radio-immunoassay);</LI>
<LI>Change in parenteral nutrition requirements; and</LI>
<LI>Adverse events related to the intervention.</LI>
</UL>
<P>Adverse events related to the intervention included:</P>
<P>A) Proportion of patients developing peripheral edema;<BR/>B)Proportion of patients developing arthralgia; and<BR/>C)Proportion of patients developing carpal tunnel syndrome.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-04-13 12:13:39 -0400" MODIFIED_BY="John K MacDonald">
<P>All publications describing randomised controlled trials of the use of human growth hormone with or without glutamine were sought through the Cochrane IBD/FBD Group Trials Register, and the Cochrane Central Register of Controlled Trials (CENTRAL) database. All studies were identified through electronic searches of MEDLINE (1966 to December 31, 2009), EMBASE (1980 to Dec 31, 2009), and CINAHL (1982 to December 31, 2009), and conference proceedings. </P>
<P>Databases were searched using the following search terms: "growth hormone," "glutamine," "intestinal rehabilitation," "intestinal adaptation," "intestinal failure", "malabsorption" and "short-bowel syndrome." There were no language restrictions. </P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-04-13 12:14:12 -0400" MODIFIED_BY="John K MacDonald">
<P>
<B>Selection of trials<BR/>
</B>Four authors (AN, YJ, ND and PW) independently assessed all published articles identified as potentially relevant by the literature search for inclusion in the review using the criteria outlined above.</P>
<P>
<B>Evaluation of methodological quality of trials<BR/>
</B>Standard methods of the Cochrane Inflammatory Bowel Disease and Functional Disorder Group were used to assess the methodological quality of studies.</P>
<P>Two authors (AN,JY) independently assessed the quality of the included studies using the Cochrane risk of bias tool (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>): An assessment was made of the method of allocation generation (i.e. was the allocation sequence adequately generated?), allocation concealment (i.e. was allocation adequately concealed?), blinding (i.e. was knowledge of the allocated intervention adequately prevented during the study?), and incomplete outcome data (i.e. were incomplete outcome data adequately addressed?). A judgement of 'Yes' indicates low risk of bias, 'No' indicates high risk of bias, and 'Unclear' indicates unclear or unknown risk of bias. </P>
<P>
<BR/>
<B>Data extraction<BR/>
</B>Two authors (AN and JY) independently extracted data from the retrieved articles. The primary authors of any articles for which there was inadequate data were contacted for further information. Any discrepancies were resolved by discussion and consensus with a third reviewer.</P>
<P>
<B>Statistical analysis</B>
</P>
<P>The statistical analysis was performed using RevMan 5 software. Heterogeneity was assessed using the chi-square (Q test) and the I<SUP>2</SUP> statistic. If the results of these tests showed heterogeneity, using a cut-off of 0.10 or larger in the Q test or more than 50% heterogeneity using the I<SUP>2</SUP> statistic, a random effects model was used for meta-analysis. Follmann's method was used for cross-over studies. A correlation coefficient of 0.4 was used to calculate the standard error of the mean difference. The quantities of the mean difference and the standard error of the mean difference were then entered into RevMan and analysed using a generic inverse variance outcome. Sensitivity analyses were performed using correlation coefficients of 0.3 and 0.5 to test the robustness of the results.</P>
<P>Subgroup analysis included:<BR/>
</P>
<UL>
<LI>Patients given only HGH;</LI>
<LI>Long versus short duration of treatment (4 weeks duration as a cut-off);</LI>
<LI>Inflammatory versus non-inflammatory cause of short bowel; and</LI>
<LI>Presence / absence of colon.</LI>
</UL>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-04-13 12:15:23 -0400" MODIFIED_BY="John K MacDonald">
<STUDY_DESCRIPTION MODIFIED="2010-04-13 12:14:44 -0400" MODIFIED_BY="John K MacDonald">
<P>The literature search identified nine randomised controlled trials that were considered for inclusion. Two studies were excluded. <LINK REF="STD-Byrne-1995a" TYPE="STUDY">Byrne 1995a</LINK> was excluded because it was a non-randomised trial. <LINK REF="STD-Scoplapio-2001" TYPE="STUDY">Scoplapio 2001</LINK> was excluded because it used glutamine without HGH. Of the seven remaining studies two studies were secondary publications (Scolapio 1999; Jeppesen 2001) of the same patients with different outcomes of the <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK> and <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> studies respectively. Therefore, five studies were included in this review.</P>
<P>
<B>Participants<BR/>
</B>
<BR/>
<LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK> was a randomised, double-blind, placebo-controlled crossover study. Criteria for eligibility included stable short bowel syndrome, i.e., at least 10% below premorbid body weight with stable (± 2 Kg) weight and nutritional support during the last 6 months. Ten patients (3 women, 7 men, mean age 49 years, range 30 to 72 years) with short bowel syndrome due to surgery for Crohn's disease were included in this trial. The mean small bowel length was 130 cm (range 90 to 170 cm). Four patients had an intact colon.</P>
<P>The <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK> trial was a randomised, double-blind, placebo-controlled crossover study. Eight patients with short bowel syndrome (6 men, 2 women, mean age 12.9 years, range 3 to 19 years) who were dependent on home parenteral nutrition were included. Seven patients had short bowel syndrome due to Crohn's disease and one following ischemia. The mean small bowel length was 71 cm (range 55 to 120 cm). Two patients had an intact colon.</P>
<P>
<LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> was a randomised, double-blind, placebo-controlled crossover study. The trial included 8 patients (one man, 7 women, age range 32 to 74 years) with short bowel syndrome. Six patients had short bowel due to Crohn's disease and 2 due to mesenteric infarction. The mean small bowel length was 100 cm; range 30-150 cm. Four of whom had their colon intact.</P>
<P>
<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> performed a randomised, placebo-controlled crossover study in 12 patients (mean age 35 years, range 19-51) with established short bowel syndrome caused by Crohn's (n = 3), mesenteric infarction (n = 3), small bowel volvulus (n = 2), necrotising enterocolitis (n = 2), abdominal wall defect (n = 1) and radiation enteritis (n = 1). The mean small bowel length was 48 cm (range 0 to 120 cm). Nine patients had a partial colon.</P>
<P>
<LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK> performed a prospective, double-blind, randomised, placebo-controlled clinical trial in 41 adult short bowel syndrome patients adults dependent on parenteral nutrition (PN). Eligibility criteria included: adults aged 18 to 75 years; body mass index (BMI) 17 to 28 kg/m<SUP>2</SUP>; small intestinal length &#8804; 200 cm; the ability to ingest solid food while requiring &#8805; 3000 PN calories/week; acceptable liver and kidney function; and normal or stable cardiovascular status. Patients had to have undergone bowel resection &#8805; 6 months prior to study, and had intact stomach and duodenum and one or more of the following: 1) &gt;= 30% of colon anastomosed to &#8805; 15 cm jejunum-ileum; 2) &lt; 30% colon anastomosed to &#8805; 90 cm jejunum-ileum; or 3) &lt; 3 L stool output/day. Total length of residual bowel was documented at the time of resection or, if operative reports were unavailable or unclear, from radiographic examinations, which were used in 2 individuals.</P>
<P>
<B>Intervention<BR/>
</B>
<BR/>
<LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK>
<BR/>Recombinant HGH in a dose of (0.024 mg/kg/day) or identical placebo were administered subcutaneously each evening by the patients. Patients received the intervention or placebo for 8 weeks separated by a washout period of12 weeks.</P>
<P>
<LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK>
<BR/>Active treatment included subcutaneous recombinant HGH (0.14 mg/kg/day), oral glutamine (0.63 g/kg per day), and a high carbohydrate low fat diet for 21 days. Subcutaneous injections of normal saline served as a placebo for HGH and polycose powder as a placebo for glutamine. A washout period was not reported.</P>
<P>
<LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK>
<BR/>Active treatment consisted of subcutaneous recombinant HGH (0.14 mg/kg/day) divided into two daily injections, oral L-glutamine (30 g/day) divided into six doses, and parenteral glutamine as glutamine enriched infusions which matched the patients' usual parenteral intake of amino acid nitrogen. Placebo treatment consisted of subcutaneous injections of saline serving as a control for growth hormone, L-alanine powder 30 g/day in six daily doses as a control for oral glutamine, and the patient's usual parenteral programme as a control for the glutamine enriched solutions. Each treatment period lasted 28 days. There was no washout period between active treatment and placebo.</P>
<P>
<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK>
<BR/>Treatment consisted of 3 weeks of recombinant HGH (0.05 mg/kg per day) without glutamine. Placebo vials contained water and were visually indistinguishable from active treatment. The two 3-week treatment periods were separated by a 1 week washout period.</P>
<P>
<LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK>
<BR/>There were three treatment groups: 1) oral glutamine (30 g/day) + subcutaneous HGH placebo; 2) oral glutamine placebo + subcutaneous HGH (0.1 mg/kg/day); or 3) oral glutamine + HGH (using the doses noted above).</P>
<P>The first group, which represented the effects of optimal dietary intake + oral Gln, served as a control. In-house treatment continued for 4 weeks. Throughout the in-house period, patients were monitored by taking vital signs, weight, oral and parenteral intakes, stool and urine output, bioelectrical impedance (model 101A, RJL Systems, Clinton, MI), and selected blood concentrations at appropriate intervals. The PN was adjusted based on pre-established weaning criteria.</P>
<P>At the conclusion of the in-house period, patients were discharged home on the optimal diet with glutamine or glutamine placebo. Their discharge PN prescription was the same as that received during the last week of their in-house therapy. All patients were monitored by their physicians and the study team for the next 3 months. If indicated by changes in nutritional and hydration status, adjustments were made in PN. At week 18, a physical examination, body weight, nutritional history, and blood studies were obtained.</P>
<P>
<B>Outcomes</B>
</P>
<P>
<LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK>
<BR/>Body weight was recorded each morning, in light clothing after voiding, but before breakfast, on statmos scale to the nearest 0.1 Kg. Lean tissue mass, body fat, bone mineral content and bone mineral density were measured by dual energy x-ray absorptiometry (DEXA). Energy content was determined by combustion in a bomb calorimeter; nitrogen in fecal samples and food duplicates was analysed by a modified Kjeldahl technique. Absorptive capacity in percent was expressed as (1 - (excretion/intake)) × 100. Blood samples were analysed in one batch for insulin-like growth factor-1 (IGF-1) by radioimmunoassay.</P>
<P>
<LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK>
<BR/>Body weight was recorded daily before breakfast.The patients wore light clothing. Lean body mass and percent body fats were measured by dual energy x-ray absorptiometry (DEXA scan). Fecal nitrogen and fat were measured by macro-Kjeldahl method and the gravimetric technique. The percent of nutrient absorption was calculated by subtracting stool losses from enteral intake divided by the enteral intake and multiplied by 100. D-xylose was used to test intestinal carbohydrate malabsorption. Serum IGF-1 level was measured by radioimmunoassay.</P>
<P>
<LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK>
<BR/>Jeppesen 2001) Weight was measured daily. The wet weight of the diet was calculated as the total weight of food and beverages, and ostomy output was calculated as the wet weight of faeces. Absorption of wet weight was calculated as the difference between these two values. Intestinal absorption was calculated as the difference between oral intake and faecal loss. Energy was measured by two different methods: bomb calorimetry or by summarising the energy values of carbohydrates, fat, and proteins (calculated on the assumption that all nitrogen originated from protein). Blood was obtained weekly for measurement of serum insulin-like growth factor 1 (IGF-1).</P>
<P>
<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK>
<BR/>Body weight and height were recorded to the nearest 0.1 kg and 0.5 cm, respectively. The oral metabolizable energy was calculated by subtracting the amount of energy excreted in stool output from that actually ingested, which corresponded to the difference between control-duplicate meals and leftovers of served meals. Nitrogen, fat and total energy content were determined by nitrogen elemental analysis using the method of van de Kamer and bomb calorimetry, respectively. Stool output was collected daily. Bioelectric impedance analysis was also performed to assess body composition. For the D-xylose test, fasted patients ingested 25 g D-xylose with 250 ml water and serum D-xylose level was determined after 2 hours using a colorimetric method. Fasting blood samples were taken and serum was stored at -80°C to assess IGF-1.</P>
<P>
<LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK>
<BR/>The primary objective of this study was to evaluate the change in PN measured in week 2 (last week of baseline period) versus week 6 (last week of treatment). The primary endpoint was PN volume; secondary endpoints were changes in PN calories and frequency of administration. A second objective was to evaluate the durability of any treatment effect over time. Thus, the endpoints measured on week 18 were compared with those variables at baseline. A third objective was to evaluate the safety of treatment.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-04-13 12:14:46 -0400" MODIFIED_BY="John K MacDonald">
<P>The Cochrane risk of bias tool indicates that the risk of bias was low for all of the 5 included studies (See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). All included studies were randomised controlled trials and all achieved adequate allocation concealment. All of the trials were double blind. All of the trials achieved complete follow up to their patients.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-04-13 12:15:23 -0400" MODIFIED_BY="John K MacDonald">
<P>Five studies met the inclusion criteria (<LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK>; <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK>; <LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK>; <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK>; <LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK>)and were included in the review. All studies included in this review except for <LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK> were cross-over trials. Follmann's technique was used for pooling data from cross-over studies.</P>
<P>
<B>Primary outcome:<BR/>
</B>
<BR/>
<B>Change in Body weight (Kg)</B>
<BR/>
<LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK> and <LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> reported a statistically significant change in body weight among the intervention group compared to placebo, while <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> did not find a significant change in weight comparing both arms. <LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK> reported results by comparing both arms to baseline. <LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK> found that body weight decreased from pretreatment (screening) to end of follow-up, but there was no significant difference between treatment groups. Decreases in weight were correlated with pretreatment BMI (R = 0.5, P = 0.001) and the average body weights of the groups remained within 3% of ideal body weight. Data were pooled from 3 studies (<LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK>;<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK>; <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK>) for the purpose of meta-analysis. The results of this meta-analysis showed a statistically significant effect of HGH with or without glutamine in increasing the body weight of these patients (MD 1.66 Kg, 95%CI 0.69 to 2.63; P = 0.0008; See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) at the end of therapy.</P>
<P>
<B>Secondary outcomes:</B>
</P>
<P>
<B>1) Change in lean body mass<BR/>
</B>
<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK>, <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> and <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK> reported a statistically significant increase in lean body mass (LBM) in the intervention group compared to placebo. <LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK> reported a statistically significant change in LBM the intervention arm compared to baseline. Pooled estimates were calculated for 3 studies and the results showed a statistically significant effect of HGH with or without glutamine in increasing LBM in comparison to placebo (MD 1.93 Kg; 95% CI 0.97 to 2.90; P = 0.0001; See <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>
<B>2) Energy absorption</B>:<BR/>
<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> was reported a statistically significant increase in energy absorption following the active intervention. <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> and <LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK> reported non significant changes in energy absorption. <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK> did not report results related to energy absorption. The results of the meta-analysis of 3 trials revealed a statistically significant effect of the intervention on increasing energy absorption (MD 4.42 Kcal; 95% CI 0.26 to 8.58; P = 0.04; See <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>
<B>3) Nitrogen absorption:</B>
<BR/>
<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> reported a significant increase in nitrogen absorption among the intervention group compared to placebo. <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> and <LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK> reported a non significant change in nitrogen absorption. <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK> did not report results related to nitrogen absorption. The pooled analysis showed a statistically significant increase in nitrogen absorption (MD 44.85 g; 95% CI 0.20 to 9.49; P = 0.04).</P>
<P>
<B>4) Fat absorption</B>:<BR/>
<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK>, <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK> and <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> did not report a significant increase in fat absorption following the intervention. However, the results of meta-analysis using 2 of these studies showed a significant effect of the intervention in increasing fat absorption (MD 5.02 g; 95% CI 0.21 to 9.82; P = 0.04; See <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>
<B>5) Carbohydrate absorption:</B>
<BR/>
<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> reported a statistically significant increase in the amount of carbohydrates absorbed after the intervention compared to placebo. <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> did not find any difference in cabohydrate absorption. The pooled analysis showed no difference in carbohydrate absorption.</P>
<P>
<B>6) Serum IGF-1:</B>
<BR/>
<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> and <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK> reported a statistically significant rise in serum IGF-1 levels in the intervention arms. While <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> and <LINK REF="STD-Elleg_x00e5_rd-1997" TYPE="STUDY">Ellegård 1997</LINK> reported a non significant change. A meta-analysis for this outcome was not performed as data to calculate Follmann's formula were only available for one study. </P>
<P>
<B>7) Parenteral nutrition requirements: </B>
<BR/>
<LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK> reported that patients who recieved HGH, glutamine and diet manipulation had the greatest decrease in PN volume (7.7± 3.2 L per week), PN calories (5751±2082 calories/week) and infusions (4 ± 1 infusions/week) compared to both HGH and glutamine placebo (volume 5.9±3.8 L per week; calories 4338 ± 1858 cal/week; infusions 3 ± 2 weeks) and the gluamine only group (volume 3.8 ± 2.4 L per week; calories 2633 ± 1341 cal/week; infusions 2 ± 1/week). At 3 months follow-up only patients who recieved HGH, glutamine and diet manipulation, maintained a statistically significant reduction in PN (P &lt; 0.005).<BR/>
<BR/>
<B>8) Adverse events:<BR/>
</B>
</P>
<UL>
<LI>Peripheral edema was reported in 6 (75%) patients by <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK>, in 30 (75%) patients by (<LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK>) and in all 8 patients by <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK>. The overall frequency for these sudies is 44/57 (77%).</LI>
</UL>
<UL>
<LI>Arthralgia was reported in 2 patients one in each study (<LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> ;<LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK>). The overall rate of arthalgia was 2/20 (10%).</LI>
</UL>
<UL>
<LI>Carpal tunnel syndrome was reported in 2/8 patients by (<LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK>) and in 14/41 patients by (<LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK>). The overall rate of carpal tunnel syndrome was16/49 (32%).</LI>
</UL>
<UL>
<LI>Other minor complications included: nausea, muscle stiffness and transient gynaecomastia.</LI>
</UL>
<P>
<BR/>
<B>Subgroup analysis</B>
</P>
<P>
<B>Studies using growth hormone only:</B>
<BR/>Separate meta-analyses including studies that used HGH only showed statistically significant changes in weight (MD 1.81 Kg; 95% CI 0.77 to 2.85; P = 0.0006), LBM (MD 2.09 Kg; 95%CI 0.99 to 3.19; P = 0.00002) and nitrogen absorption (MD 5.81g; 95% CI 0.06 to 11.67; P = 0.05) in favour of the intervention. No significant change in energy absorption was observed.</P>
<P>
<B>Duration of treatment:</B>
<BR/>One study had duration of more than 4 weeks in both arms. While 3 studies had a duration of 4 weeks or less. We were able to pool the estimates for 2 of the studies with short durations only. The results showed a statistically significant change in weight (MD 1.71 Kg; 95% CI 0.44 to 2.97; P=0.008) and LBM (MD 2 Kg, 95% CI 0.83 to 3.17; P = 0.0008), but not in energy or nitrogen absorption.</P>
<P>
<B>Causes of short bowel syndrome/ presence or absence of colon:</B>
<BR/>We were not able to do a subgroup analysis for the underlying cause of short bowel (inflammatory versus non-inflammatory) or the presence or absence of the colon, due to unavailability of the individual data.</P>
<P>
<B>Sensitivity analysis: </B>
<BR/>Sensitivity analyses were performed using correlation coefficients of 0.3 and 0.5. The results were unchanged and this revealed robustness of our results. Individual results are not shown.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-04-13 12:36:16 -0400" MODIFIED_BY="John K MacDonald">
<P>The management of patients who have intestinal failure secondary to short bowel syndrome remains an area of great importance because of the tremendous morbidity and expense of treatment. The suggestion that several physiochemical factors such as growth hormone and glutamine, may promote adaptation of the remnant intestine, has led to a number of animal experiments and clinical trials.</P>
<P>Evidence supporting the use of HGH in short bowel syndrome includes the fact that exogenous growth hormone stimulates structural and functional intestinal adaptation in rats (<LINK REF="REF-Shulman-1992" TYPE="REFERENCE">Shulman 1992</LINK>), and that while hypophysectomy impairs intestinal adaptation, growth hormone normalises it (<LINK REF="REF-Yeh-1978" TYPE="REFERENCE">Yeh 1978</LINK>). It was also found that exogenous growth hormone administration enhances fluid and electrolyte absorption and nutrient transport in human gut (<LINK REF="REF-Inoue-1994" TYPE="REFERENCE">Inoue 1994</LINK>). Furthermore, there has been evidence that transgenic mice with chronic growth hormone excess demonstrate significantly increased growth of small bowel mucosa (<LINK REF="REF-Ulshen-1993" TYPE="REFERENCE">Ulshen 1993</LINK>). The amino acid glutamine has been shown to be trophic to the intestine and to enhance nutrient absorption (<LINK REF="REF-Gouttebel-1992" TYPE="REFERENCE">Gouttebel 1992</LINK>, <LINK REF="REF-Scheppach-1994" TYPE="REFERENCE">Scheppach 1994</LINK>).</P>
<P>In rats growth hormone and IGF-1 both increase protein synthesis in jejunal muscularis externa but only IGF-1 stimulates jejunal mucosal growth. The effect of growth hormone is mediated through IGF-1 and its receptors are expressed throughout the gut and it originates from the mesenchymal cells of the lamina propria. IGF-1 may act in paracrine and autocrine fashion (<LINK REF="REF-Lund-1998" TYPE="REFERENCE">Lund 1998</LINK>). Exogenous growth hormone increases serum IGF-1 levels, as well as, intestinal IGF-1 levels. Mucosal growth may be stimulated by IGF-1 induced DNA and protein production, in part mediated by increased ornithine decarboxylase activity and subsequent nucleotide synthesis (<LINK REF="REF-Dowling-1992" TYPE="REFERENCE">Dowling 1992</LINK>) Glutamine is a substrate for ornithine decarboxylase. Therefore, there is interest in the synergistic effect of glutamine administration given with growth hormone.</P>
<P>In this systematic review we reviewed all randomised clinical trials looking at the effect of growth hormones with or without glutamine as a management modality for patients with short bowel syndrome. The results demonstrated an increase in weight, lean body mass and absorptive capacities at the end of therapy for these patients, but the benefit disappears after the therapy is stopped. <LINK REF="STD-Byrne-2005" TYPE="STUDY">Byrne 2005</LINK> reported a sustained reduction in PN volume, calories and number of infusions in patients who recieved HGH, glutamine and diet manipulation at 3 month follow-up. Sensitivity analyses using correlation coefficients of 0.3 and 0.5 revealed the robustness of the primary pooled analyses.</P>
<P>There was a high degree of statistical heterogeneity between the studies used in the meta-analysis in regard to energy, fat and nitrogen absorption. Subgroup analyses were performed to investigate this heterogeneity. We believe there are several reasons for the inconsisent results seen between the studies. The first relates to the different methods used by the authors to assess outcome. Some studies used bomb calorimetry to measure energy absorption while others calculated it by substracting the amount of energy excreted in stool from that actually ingested. Individually, all trials failed to show a significant increase in fat absorption, but pooled estimates that included results from <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK> and <LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> showed a positive effect on fat absorption at the end of therapy.</P>
<P>Another potential explanation for inconsistency in results between trials relates to patient heterogeneity. Differences in bowel anatomy and underlying diagnosis may impact the response to HGH. For example, patients with mucosal disease may not absorb or adapt as well as those with healthy mucosa. Patients with Crohn's disease or radiation injury tend to have a more variable response to interventions than those with short bowel syndrome resulting from mesenteric ischemia. The degree of malnutrition also influences a patient's ability to adapt and respond to anabolic hormones. If the patient was malnourished at the initiation of treatment, it is not likely they would respond optimally. Patient age and duration of intestinal failure may also impact treatment efficacy. It is possible that treatment response may be more significant or sustained if delivered during the phase of active adaptation. Infants who are developing actively may also respond better to treatment. However, the long term neoplastic risk of therapy is unknown.</P>
<P>Another important observation from rodent models may explain the difference in these clinical studies. GH-infused, TPN-fed rats have been shown to have reduced responsiveness to endogenous IGF-1 over time (<LINK REF="REF-Lund-1998" TYPE="REFERENCE">Lund 1998</LINK>). Lack of effect of excess GH on crypt cell production in adult transgenic mice appears to reflect a compensatory response to prolonged GH excess (<LINK REF="REF-Dahly--2004" TYPE="REFERENCE">Dahly 2004</LINK>). These observations may in part explain why <LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> found a positive response, i.e. increased absorption, with a lower dose of HGH, compared with the 2 controlled studies that used a higher dose of HGH. However, <LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK> reported a return of the absorptive response to baseline after the 1-week washout period in patients who were first randomised to receive HGH. These observations question the sustained effects of HGH. Therefore, heterogeneity in dose and duration between studies could impact results.</P>
<P>Glutamine is required for ornithine decarboxylase and is essential for nucleotide biosynthesis. It is believed that HGH and glutamine should have a synergistic effect on intestinal adaptation. <LINK REF="STD-Scolapio-1997" TYPE="STUDY">Scolapio 1997</LINK> and <LINK REF="STD-Szkudlarek-2000" TYPE="STUDY">Szkudlarek 2000</LINK>reported no significant improvement in absorptive capacity , although there was a higher level of IGF-1 in these trials compared to <LINK REF="STD-Seguy-2003" TYPE="STUDY">Seguy 2003</LINK>. Subgroup analysis of therapy duration, etiology of short bowel syndrome and presence or absence of the colon did not show significant results and were limited by unavailable data from the original publications.</P>
<P>The results of this systematic review suggest that treatment with HGH may provide benefit in terms of weight gain and fat absorption. However, given the small number of patients enrolled in these studies these results should be interpreted with caution. Furthermore, in most of the studies the effects of therapy were short lived, with outcomes returning to baseline values shortly after cessation of therapy. There is no conclusive evidence that the addition of glutamine enhances a growth hormone response. According to <LINK REF="REF-Flint-1912" TYPE="REFERENCE">Flint 1912</LINK> , the process of intestinal adaptation is most active during the acute stage (i.e. after bowel resection) and then slows down. It may be that these drugs are more effective if given early. To date, most data suggest the benefits of HGH are short lived and did not translate into significant weaning on PN. HGH may not be justified when considering efficacy and cost.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-04-13 12:15:53 -0400" MODIFIED_BY="John K MacDonald">
<IMPLICATIONS_PRACTICE MODIFIED="2010-04-13 12:15:51 -0400" MODIFIED_BY="John K MacDonald">
<P>The available evidence from this systematic review on the role of HGH with or without glutamine as a therapeutic modality in patients with chronic short bowel syndrome suggests a possible short-term benefit in terms of weight gain and fat absorption. However, given the small numbers of patients enrolled in these studies these results need to be interpreted with caution. Furthermore, the benefits of treatment were not sustained after cessation of therapy in all but one study. Prolonged treatment with HGH and glutamine may be necessary, but long term safety is unknown.  The data suggests low dose therapy may be more beneficial than higher dose therapy.  The evidence is inadequate to determine the ideal duration of therapy and more importantly the safety concerns in that regard.  It is not known whether efficacy would be improved if HGH was utilized during the early phase of adaptation or in the paediatric population during rapid gut development.  At this time, the available literature does not endorse the routine use of HGH or glutamine in short bowel syndrome.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-04-13 12:15:53 -0400" MODIFIED_BY="John K MacDonald">
<P>A placebo-controlled randomised trial evaluating HGH during the active phase of adaptation would be helpful. This trial could be designed as a direct comparison and not a crossover design. A third arm of treatment such as higher dose therapy or duration could be added. Due to the relatively small population of patients this would likely need to be done as a multi-center trial. The role of HGH in the infant population would also be interesting to explore, but concerns regarding somatic growth and possible neoplasia need to be considered. All studies should be performed using consistent methods to assess outcomes. Longterm safety implications also need to be assessed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-03-18 07:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>Department of Health Policy, Management and Evaluation, University of Toronto.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>No conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-03-18 07:20:08 -0400" MODIFIED_BY="[Empty name]">
<P>Dr Nasr selected trials, assessed trial quality, extracted data, analysis, wrote and edited the final review.</P>
<P>Dr Wales selected trials, assessed trial quality, extracted data, wrote and edited the final review.</P>
<P>Ms. De Silva selected trials, assessed trial quality, extracted data, and edited the final review.</P>
<P>Ms. Yamada selected trials, assessed trial quality, extracted data, and edited the final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-04-13 09:23:14 -0400" MODIFIED_BY="John K MacDonald">
<STUDIES MODIFIED="2010-04-12 08:31:41 -0400" MODIFIED_BY="John K MacDonald">
<INCLUDED_STUDIES MODIFIED="2010-04-12 08:31:41 -0400" MODIFIED_BY="John K MacDonald">
<STUDY DATA_SOURCE="PUB" ID="STD-Byrne-2005" MODIFIED="2010-04-12 08:07:21 -0400" MODIFIED_BY="John K MacDonald" NAME="Byrne 2005" YEAR="">
<REFERENCE MODIFIED="2010-04-12 08:07:21 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Byrne TA, Wilmore DW, Iyer K, Dibaise J, Clancy K, Robinson MK, et al</AU>
<TI>Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial</TI>
<SO>Ann Surg</SO>
<YR>2005</YR>
<VL>242</VL>
<NO>5</NO>
<PG>655-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16244538"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elleg_x00e5_rd-1997" MODIFIED="2009-04-22 09:10:51 -0400" MODIFIED_BY="[Empty name]" NAME="Ellegård 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-04-21 08:50:15 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellegård L, Bosaeus I, Nordgren S, Bengtsson BA</AU>
<TI>Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome</TI>
<SO>Ann Surg</SO>
<YR>1997</YR>
<VL>225</VL>
<NO>1</NO>
<PG>88-96</PG>
<IDENTIFIERS MODIFIED="2009-04-21 08:50:15 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 08:50:15 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8998124"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scolapio-1997" MODIFIED="2010-04-12 08:29:02 -0400" MODIFIED_BY="John K MacDonald" NAME="Scolapio 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-04-12 08:27:25 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scolapio JS, Camilleri M, Fleming CR, Oenning LV, Burton DD, Sebo TJ, et al</AU>
<TI>Effect of growth hormone, glutamine and diet on adaptation in short-bowel syndrome: a randomized, controlled study</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>113</VL>
<NO>4</NO>
<PG>1074-81</PG>
<IDENTIFIERS MODIFIED="2009-04-21 09:34:15 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 09:34:15 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9322500"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-12 08:29:02 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scolapio JS</AU>
<TI>Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomized controlled study</TI>
<SO>JPEN J Parenter Enteral Nutr</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>6</NO>
<PG>309-12</PG>
<IDENTIFIERS MODIFIED="2010-04-12 08:28:38 -0400" MODIFIED_BY="John K MacDonald">
<IDENTIFIER MODIFIED="2010-04-12 08:28:38 -0400" MODIFIED_BY="John K MacDonald" TYPE="PUBMED" VALUE="10574477"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seguy-2003" MODIFIED="2009-04-21 10:10:09 -0400" MODIFIED_BY="[Empty name]" NAME="Seguy 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-21 10:10:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seguy D, Vahedi K, Kapel N, Souberbielle JC, Messing B</AU>
<TI>Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<NO>2</NO>
<PG>293-302</PG>
<IDENTIFIERS MODIFIED="2009-04-21 10:10:09 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 10:10:09 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12557135"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szkudlarek-2000" MODIFIED="2010-04-12 08:31:30 -0400" MODIFIED_BY="John K MacDonald" NAME="Szkudlarek 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-04-12 08:31:30 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeppesen PB, Szkudlarek J, Høy CE, Mortensen PB</AU>
<TI>Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study</TI>
<SO>Scand J Gastroenterol 2001</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>1</NO>
<PG>48-54</PG>
<IDENTIFIERS MODIFIED="2010-04-12 08:31:12 -0400" MODIFIED_BY="John K MacDonald">
<IDENTIFIER MODIFIED="2010-04-12 08:31:12 -0400" MODIFIED_BY="John K MacDonald" TYPE="PUBMED" VALUE="11218239"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-12 08:29:58 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Szkudlarek J, Jeppesen PB, Mortensen PB</AU>
<TI>Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomized, double blind, crossover, placebo controlled study</TI>
<SO>Gut</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>2</NO>
<PG>199-205</PG>
<IDENTIFIERS MODIFIED="2009-04-21 10:01:55 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 10:01:55 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10896910"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-04-12 08:11:26 -0400" MODIFIED_BY="John K MacDonald">
<STUDY DATA_SOURCE="PUB" ID="STD-Byrne-1995a" MODIFIED="2010-04-12 08:11:26 -0400" MODIFIED_BY="John K MacDonald" NAME="Byrne 1995a" YEAR="1995">
<REFERENCE MODIFIED="2009-04-22 09:14:42 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Byrne TA, Persinger RL, Young LS, Ziegler TR, Wilmore DW</AU>
<TI>A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet</TI>
<SO>Ann Surg</SO>
<YR>1995</YR>
<VL>222</VL>
<NO>3</NO>
<PG>243-54</PG>
<IDENTIFIERS MODIFIED="2009-04-21 10:08:39 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 10:08:39 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7677455"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scoplapio-2001" MODIFIED="2009-04-21 10:14:37 -0400" MODIFIED_BY="[Empty name]" NAME="Scoplapio 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-21 10:14:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scolapio JS, McGreevy K, Tennyson GS, Burnett OL</AU>
<TI>Effect of glutamine in short-bowel syndrome</TI>
<SO>Clin Nutr</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>4</NO>
<PG>319-23</PG>
<IDENTIFIERS MODIFIED="2009-04-21 10:14:37 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 10:14:37 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11478829"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-04-13 09:23:14 -0400" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_REFERENCES MODIFIED="2010-04-13 09:23:14 -0400" MODIFIED_BY="John K MacDonald">
<REFERENCE ID="REF-Abu_x002d_Elmagd-1994" MODIFIED="2009-04-22 09:55:11 -0400" MODIFIED_BY="[Empty name]" NAME="Abu-Elmagd 1994" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Elmagd K, Todo S,Tzakis A, Reyes J, Nour B, Furukawa H, et al</AU>
<TI>Three years of clinical experience with intestinal transplantation</TI>
<SO>J Am Coll Surg</SO>
<YR>1994</YR>
<VL>179</VL>
<NO>4</NO>
<PG>385-400</PG>
<IDENTIFIERS MODIFIED="2009-04-21 10:20:05 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 10:20:05 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7522850"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Byrne-1995b" MODIFIED="2010-04-12 08:11:53 -0400" MODIFIED_BY="John K MacDonald" NAME="Byrne 1995b" TYPE="JOURNAL_ARTICLE">
<AU>Byrne TA, Morrissey TB, Nattakom TV, Ziegler TR, Wilmore DW</AU>
<TI>Growth hormone, glutamine and a modified diet enhanced nutrient absorption in patients with severe short bowel syndrome</TI>
<SO>JPEN J Parenter Enteral Nutr</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>4</NO>
<PG>296-302</PG>
<IDENTIFIERS MODIFIED="2009-04-21 10:21:52 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 10:21:52 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8523629"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dahly--2004" MODIFIED="2009-04-21 10:28:25 -0400" MODIFIED_BY="[Empty name]" NAME="Dahly  2004" TYPE="JOURNAL_ARTICLE">
<AU>Dahly EM, Miller ME, Lund PK, Ney DM</AU>
<TI>Postreceptor resistance to exogenous growth hormone exists in the jejunal mucosa of parenterally fed rats</TI>
<SO>J Nutr</SO>
<YR>2004</YR>
<VL>134</VL>
<NO>3</NO>
<PG>530-7</PG>
<IDENTIFIERS MODIFIED="2009-04-21 10:28:25 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 10:28:25 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14988442"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dowling-1992" MODIFIED="2010-04-12 14:35:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Dowling 1992" TYPE="JOURNAL_ARTICLE">
<AU>Dowling RH</AU>
<TI>Cellular and molecular basis of intestinal and pancreatic adaptation</TI>
<SO>Scand J Gastroenterol Suppl</SO>
<YR>1992</YR>
<VL>193</VL>
<PG>64-7</PG>
<IDENTIFIERS MODIFIED="2010-04-12 14:35:23 -0400" MODIFIED_BY="John K MacDonald">
<IDENTIFIER MODIFIED="2010-04-12 14:35:23 -0400" MODIFIED_BY="John K MacDonald" TYPE="PUBMED" VALUE="1290060"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Flint-1912" MODIFIED="2009-04-21 10:30:24 -0400" MODIFIED_BY="[Empty name]" NAME="Flint 1912" TYPE="JOURNAL_ARTICLE">
<AU>Flint JM</AU>
<TI>The effect of extensive resection of small intestine</TI>
<SO>Bull Johns Hopkins Hosp</SO>
<YR>1912</YR>
<VL>23</VL>
<PG>127-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gardemann-1992" MODIFIED="2009-04-22 10:00:01 -0400" MODIFIED_BY="[Empty name]" NAME="Gardemann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Gardemann A, Watanabe Y, Grosse V, Hesse S, Jungermann K</AU>
<TI>Increases in intestinal glucose absorption and hepatic glucose uptake elicited by luminal but not vascular glutamine in the jointly perfused small intestine and liver of rats</TI>
<SO>Biochem J</SO>
<YR>1992</YR>
<VL>283</VL>
<NO>Pt 3</NO>
<PG>759-65</PG>
<IDENTIFIERS MODIFIED="2009-04-22 10:00:01 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-22 10:00:01 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1590766"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gouttebel-1992" MODIFIED="2009-04-22 10:00:16 -0400" MODIFIED_BY="[Empty name]" NAME="Gouttebel 1992" TYPE="JOURNAL_ARTICLE">
<AU>Gouttebel MC, Astre C, Briand D, Saint-Aubert B, Girardot PM, Joyeux H</AU>
<TI>Influence of N-acetylglutamine or glutamine infusion on plasma acid concentration during the early phase of small bowel adaptation in the dog</TI>
<SO>JPEN J Parenter Enteral Nutr</SO>
<YR>1992</YR>
<VL>16</VL>
<NO>2</NO>
<PG>117-21</PG>
<IDENTIFIERS MODIFIED="2009-04-22 10:00:16 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-22 10:00:16 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1556804"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gu-2001" MODIFIED="2010-04-12 09:32:49 -0400" MODIFIED_BY="John K MacDonald" NAME="Gu 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gu Y, Wu ZH, Xie JX, Jin DY, Zhuo HC</AU>
<TI>Effects of growth hormone (rhGH) and glutamine supplemented parenteral nutrition on intestinal adaptation in short bowel rats</TI>
<SO>Clin Nutr</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>2</NO>
<PG>159-66</PG>
<IDENTIFIERS MODIFIED="2010-04-12 09:32:49 -0400" MODIFIED_BY="John K MacDonald">
<IDENTIFIER MODIFIED="2010-04-12 09:32:49 -0400" MODIFIED_BY="John K MacDonald" TYPE="PUBMED" VALUE="11327744"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-04-13 09:23:14 -0400" MODIFIED_BY="John K MacDonald" NAME="Higgins 2008" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration. Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inoue-1994" MODIFIED="2009-04-21 10:56:30 -0400" MODIFIED_BY="[Empty name]" NAME="Inoue 1994" TYPE="JOURNAL_ARTICLE">
<AU>Inoue Y, Copeland EM, Souba WW</AU>
<TI>Growth hormone enhance amino acid uptake by the human small intestine</TI>
<SO>Ann Surg</SO>
<YR>1994</YR>
<VL>219</VL>
<NO>6</NO>
<PG>715-22</PG>
<IDENTIFIERS MODIFIED="2009-04-21 10:56:30 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 10:56:30 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8203982"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jacobs-1983" MODIFIED="2009-04-21 12:21:26 -0400" MODIFIED_BY="[Empty name]" NAME="Jacobs 1983" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs LR</AU>
<TI>Effect of dietary fiber on mucosal growth and cell proliferation in the small intestine of the rat: a comparison of oat bran, pectin and, guar with total fibre deprivation</TI>
<SO>Am J Clin Nutr</SO>
<YR>1983</YR>
<VL>37</VL>
<NO>6</NO>
<PG>954-60</PG>
<IDENTIFIERS MODIFIED="2009-04-21 12:21:09 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 12:21:09 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="6189387"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lentze-1989" MODIFIED="2009-04-22 10:00:25 -0400" MODIFIED_BY="[Empty name]" NAME="Lentze 1989" TYPE="JOURNAL_ARTICLE">
<AU>Lentze MJ</AU>
<TI>Intestinal adaptation in short bowel syndrome</TI>
<SO>Eur J Pediatr</SO>
<YR>1989</YR>
<VL>148</VL>
<NO>4</NO>
<PG>294-9</PG>
<IDENTIFIERS MODIFIED="2009-04-22 10:00:25 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-22 10:00:25 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2651129"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Li_x002d_Ling-2001" MODIFIED="2009-04-21 12:05:21 -0400" MODIFIED_BY="[Empty name]" NAME="Li-Ling 2001" TYPE="JOURNAL_ARTICLE">
<AU>Li-Ling, Irving M</AU>
<TI>The effectiveness of growth hormone, glutamine and low fat diet containing high-carbohydrate on the enhancement of the function of remnant intestine among patients with short bowel syndrome: a review of published trials</TI>
<SO>Clin Nutr</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>3</NO>
<PG>199-204</PG>
<IDENTIFIERS MODIFIED="2009-04-21 11:54:32 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 11:54:32 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11407865"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lund-1998" MODIFIED="2009-04-22 10:04:23 -0400" MODIFIED_BY="[Empty name]" NAME="Lund 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lund PK</AU>
<TI>Molecular basis of intestinal adaptation: the role of the insulin-like growth factor system</TI>
<SO>Ann N Y Acad Sci</SO>
<YR>1998</YR>
<VL>859</VL>
<PG>18-36</PG>
<IDENTIFIERS MODIFIED="2009-04-22 10:04:23 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-22 10:04:23 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9928367"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Messing-1999" MODIFIED="2009-04-22 08:58:37 -0400" MODIFIED_BY="[Empty name]" NAME="Messing 1999" TYPE="JOURNAL_ARTICLE">
<AU>Messing B, Crenn P, Beau P, Boutron-Ruault MC, Rambaud JC, Matuchansky C</AU>
<TI>Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>5</NO>
<PG>1043-50</PG>
<IDENTIFIERS MODIFIED="2009-04-21 13:29:06 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 13:29:06 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10535866"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nighttingale-1993" MODIFIED="2009-04-21 13:31:43 -0400" MODIFIED_BY="[Empty name]" NAME="Nighttingale 1993" TYPE="JOURNAL_ARTICLE">
<AU>Nighttingale JM, Lennard-Jones JE</AU>
<TI>The short bowel syndrome. What's new and old?</TI>
<SO>Dig Dis</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>1</NO>
<PG>12-31</PG>
<IDENTIFIERS MODIFIED="2009-04-21 13:31:40 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 13:31:40 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8443953"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nighttingale-1999" MODIFIED="2009-04-22 09:32:19 -0400" MODIFIED_BY="[Empty name]" NAME="Nighttingale 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nighttingale JM</AU>
<TI>Management of patients with a short bowel</TI>
<SO>Nutrition</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>7-8</NO>
<PG>633-7</PG>
<IDENTIFIERS MODIFIED="2009-04-21 13:36:23 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 13:36:23 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10422101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rhoads-1991" MODIFIED="2009-04-22 10:04:43 -0400" MODIFIED_BY="[Empty name]" NAME="Rhoads 1991" TYPE="JOURNAL_ARTICLE">
<AU>Rhoads JM, Keku EO, Quinn J, Woosely J, Lecce JG</AU>
<TI>L-glutamine stimulates jejunal sodium and chloride absorption in pig rotavirus enteritis</TI>
<SO>Gastroenterology</SO>
<YR>1991</YR>
<VL>100</VL>
<NO>3</NO>
<PG>683-91</PG>
<IDENTIFIERS MODIFIED="2009-04-22 10:04:43 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-22 10:04:43 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 1847119"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Scheppach-1994" MODIFIED="2009-04-21 13:44:45 -0400" MODIFIED_BY="[Empty name]" NAME="Scheppach 1994" TYPE="JOURNAL_ARTICLE">
<AU>Scheppach W, Loges C, Bartram P, Christl SU, Richter F, Dusel G, et al</AU>
<TI>Effect of free glutamine and alanyl-glutamine dipeptide on mucosal proliferation of the human ileum and colon</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>107</VL>
<NO>2</NO>
<PG>429-34</PG>
<IDENTIFIERS MODIFIED="2009-04-21 13:42:28 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 13:42:28 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8039619"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shulman-1992" MODIFIED="2009-04-21 13:50:33 -0400" MODIFIED_BY="[Empty name]" NAME="Shulman 1992" TYPE="JOURNAL_ARTICLE">
<AU>Shulman DI, Hu CS, Duckett G, Lavallee-Grey M</AU>
<TI>Effects of short-term growth hormone therapy in rats undergoing 75% small intestinal resection</TI>
<SO>J Pediatric Gastroenterol Nutr</SO>
<YR>1992</YR>
<VL>14</VL>
<NO>1</NO>
<PG>3-11</PG>
<IDENTIFIERS MODIFIED="2009-04-21 13:50:33 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 13:50:33 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 1573509"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Souba-1985" MODIFIED="2009-04-21 13:53:12 -0400" MODIFIED_BY="[Empty name]" NAME="Souba 1985" TYPE="JOURNAL_ARTICLE">
<AU>Souba WW, Smith RJ, Wilmore DW</AU>
<TI>Glutamine metabolism by the intestinal tract</TI>
<SO>JPEN J Parenter Enteral Nutr</SO>
<YR>1985</YR>
<VL>9</VL>
<NO>5</NO>
<PG>608-17</PG>
<IDENTIFIERS MODIFIED="2009-04-21 13:53:12 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 13:53:12 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3900455"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tamada-1993" MODIFIED="2009-04-21 13:58:44 -0400" MODIFIED_BY="[Empty name]" NAME="Tamada 1993" TYPE="JOURNAL_ARTICLE">
<AU>Tamada H, Nezu R, Matsuo Y, Imamura I, Takagi Y, Okada A</AU>
<TI>Alanyl glutamine-enriched total parenteral nutrition restores intestinal adaptation after either proximal or distal massive resection in rats</TI>
<SO>JPEN J Parenter Enteral Nutr</SO>
<YR>1993</YR>
<VL>17</VL>
<NO>3</NO>
<PG>236-42</PG>
<IDENTIFIERS MODIFIED="2009-04-21 13:58:43 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 13:58:43 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8505828"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1993" MODIFIED="2009-04-21 14:02:26 -0400" MODIFIED_BY="[Empty name]" NAME="Thompson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Thompson JS</AU>
<TI>Surgical considerations in the short bowel syndrome</TI>
<SO>Surg Gynecol Obstet</SO>
<YR>1993</YR>
<VL>176</VL>
<NO>1</NO>
<PG>89-101</PG>
<IDENTIFIERS MODIFIED="2009-04-21 14:00:27 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 14:00:27 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8427009"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ulshen-1993" MODIFIED="2009-04-21 14:05:32 -0400" MODIFIED_BY="[Empty name]" NAME="Ulshen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Ulshen MH, Dowling RH, Fuller CR, Zimmermann EM, Lund PK</AU>
<TI>Enhanced growth of small bowel in transgenic mice overexpressing bovine growth hormone</TI>
<SO>Gastroenterology</SO>
<YR>1993</YR>
<VL>104</VL>
<NO>4</NO>
<PG>973-80</PG>
<IDENTIFIERS MODIFIED="2009-04-21 14:05:30 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-21 14:05:30 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7681797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yeh-1978" MODIFIED="2009-04-22 10:15:04 -0400" MODIFIED_BY="[Empty name]" NAME="Yeh 1978" TYPE="JOURNAL_ARTICLE">
<AU>Yeh KY, Moog F</AU>
<TI>Hormonal influences on the growth and enzymic differentiation of the small intestine of the hypophysectomized rat</TI>
<SO>Growth</SO>
<YR>1978</YR>
<VL>42</VL>
<NO>4</NO>
<PG>495-504</PG>
<IDENTIFIERS MODIFIED="2009-04-22 10:15:04 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-22 10:15:04 -0400" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="750312"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ziegler-1996" MODIFIED="2010-04-12 09:36:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Ziegler 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler TR, Mantell MP, Chow JC, Rombeau JL, Smith RJ</AU>
<TI>Gut adaptation and the insulin-like growth factor system: regulation by glutamine and IGF-1 administration</TI>
<SO>Am J Physiol 1996</SO>
<YR>1996</YR>
<VL>271</VL>
<NO>5 Pt 1</NO>
<PG>G866-75</PG>
<IDENTIFIERS MODIFIED="2010-04-12 09:36:05 -0400" MODIFIED_BY="John K MacDonald">
<IDENTIFIER MODIFIED="2010-04-12 09:36:05 -0400" MODIFIED_BY="John K MacDonald" TYPE="PUBMED" VALUE="8944702"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-04-23 14:25:18 -0400" MODIFIED_BY="John K MacDonald">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-04-23 14:25:18 -0400" MODIFIED_BY="John K MacDonald" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-04-13 09:08:12 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Byrne-2005">
<CHAR_METHODS MODIFIED="2010-04-13 09:06:45 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 11:38:37 -0500" MODIFIED_BY="[Empty name]">
<P>N= 41</P>
<P>Male:Female = 12:29<BR/>Age range 45-53 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-13 09:06:48 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomised to one of 3 groups (1:2:2 ratio): 1) oral Gln (30 g/day) + subcutaneous GH placebo; 2) oral Gln placebo + subcutaneous GH (0.1 mg/kg per day); or 3) oral Gln + GH</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-13 09:08:12 -0400" MODIFIED_BY="John K MacDonald">
<P>Changes in PN calories and frequency of administration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-13 09:07:46 -0400" MODIFIED_BY="John K MacDonald"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-04-13 09:08:50 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Elleg_x00e5_rd-1997">
<CHAR_METHODS MODIFIED="2010-04-13 09:08:34 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomised, double-blind, placebo-controlled crossover study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-13 09:08:38 -0400" MODIFIED_BY="John K MacDonald">
<P>N= 10<BR/>Male:Female = 7:3<BR/>Mean age 49 years (range 30-72 years)<BR/>Mean intestinal length =130 cm (range 90-170)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-13 09:08:45 -0400" MODIFIED_BY="John K MacDonald">
<P>Intervention: recombinant human growth hormone in a dose of 24 µg/kg- per day, administered subcutaneously each evening by the patients themselves<BR/>Placebo: Subcutaneous injections of normal saline served as a control.<BR/>Each period lasted 6 weeks<BR/>Washout period: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-13 09:08:50 -0400" MODIFIED_BY="John K MacDonald">
<P>Change in daily weight<BR/>Change in lean body mass<BR/>Change in energy and nitrogen absorption<BR/>Change in serum IGF-1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-04-23 14:25:18 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Scolapio-1997">
<CHAR_METHODS MODIFIED="2010-04-13 09:09:15 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomised, double-blind, placebo-controlled crossover study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-23 14:25:18 -0400" MODIFIED_BY="John K MacDonald">
<P>N= 8<BR/>Male:Female = 6:2<BR/>Mean age 18.9 years (range 3-19 years)<BR/>Mean intestinal length = 71 cm (range 55-120)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-13 09:09:35 -0400" MODIFIED_BY="John K MacDonald">
<P>Intervention: Subcutaneous human recombinant growth hormone (0.14 mg/kg per day), oral glutamine (0.63 g/kg per day)<BR/>Placebo: Subcutaneous injections of normal saline served as a control for growth hormone and polycose powder as a control for glutamine<BR/>Each period lasted 6 weeks<BR/>Washout period: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-13 09:09:41 -0400" MODIFIED_BY="John K MacDonald">
<P>Change in daily weight<BR/>Change in lean body mass<BR/>Change in fat absorption<BR/>Change in serum IGF-1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-04-13 09:10:55 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Seguy-2003">
<CHAR_METHODS MODIFIED="2010-04-13 09:10:35 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomised, double-blind, placebo-controlled crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-13 09:10:38 -0400" MODIFIED_BY="John K MacDonald">
<P>N= 12<BR/>Male:Female = 6:2<BR/>Mean age 35.3 years (range 19-51 years)<BR/>Mean intestinal length = 48 cm (SD 11)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-13 09:10:46 -0400" MODIFIED_BY="John K MacDonald">
<P>Intervention: 3 weeks of recombinant human GH (0.05 mg/kg per day) without glutamine<BR/>Placebo: vials contained water and were visually indistinguishable from active treatment<BR/>Each period lasted 3 weeks<BR/>Washout period: 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-13 09:10:55 -0400" MODIFIED_BY="John K MacDonald">
<P>Change in daily weight<BR/>Change in lean body mass<BR/>Change in energy and nitrogen absorption<BR/>Change in fat and carbohydrates absorption</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-04-13 09:12:30 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Szkudlarek-2000">
<CHAR_METHODS MODIFIED="2010-04-13 09:11:42 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomised, double-blind, placebo-controlled crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-13 09:11:45 -0400" MODIFIED_BY="John K MacDonald">
<P>N= 8<BR/>Male:Female = 1:7<BR/>Mean age 51 years (range 32-74 years)<BR/>Mean intestinal length = 100 cm (range 30-150)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-13 09:11:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Intervention: Subcutaneous recombinant human growth hormone (0.14 mg/kg/day) divided into two daily injections, oral L-glutamine (30 g/day divided into six doses)<BR/>Placebo: Subcutaneous injections of saline serving as a control for growth hormone, L-alanine powder 30 g/d in six daily doses as a control for oral glutamine, and the patient's usual parenteral program as a control for the glutamine enriched solutions<BR/>Each treatment period lasted 28 days<BR/>Washout period: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-13 09:12:30 -0400" MODIFIED_BY="John K MacDonald">
<P>Change in daily weight<BR/>Change in lean body mass<BR/>Change in energy and nitrogen absorption<BR/>Change in fat and carbohydrate absorption<BR/>Change in serum IGF-1</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-04-13 09:13:20 -0400" MODIFIED_BY="John K MacDonald" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-04-12 11:39:02 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Byrne-1995a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 11:39:02 -0400" MODIFIED_BY="John K MacDonald">
<P>Non randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-13 09:13:20 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Scoplapio-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-13 09:13:20 -0400" MODIFIED_BY="John K MacDonald">
<P>Used only glutamine without HGH</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-04-13 09:13:01 -0400" MODIFIED_BY="John K MacDonald">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-04-13 09:12:40 -0400" MODIFIED_BY="John K MacDonald" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:05:37 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Byrne-2005">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:07:12 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Elleg_x00e5_rd-1997">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:09:51 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Scolapio-1997">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:11:07 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Seguy-2003">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:12:40 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Szkudlarek-2000">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-04-13 09:12:42 -0400" MODIFIED_BY="John K MacDonald" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:04:14 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Byrne-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:07:15 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Elleg_x00e5_rd-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:09:55 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Scolapio-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:11:09 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Seguy-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:12:42 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Szkudlarek-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-04-13 09:12:49 -0400" MODIFIED_BY="John K MacDonald" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-04-13 09:05:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Byrne-2005">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-04-13 09:07:20 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Elleg_x00e5_rd-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-04-13 09:10:01 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Scolapio-1997">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-04-13 09:11:15 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Seguy-2003">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-04-13 09:12:49 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Szkudlarek-2000">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-04-13 09:13:01 -0400" MODIFIED_BY="John K MacDonald" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-13 09:06:25 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Byrne-2005">
<DESCRIPTION>
<P>One patient dropped out of the HGH + glutamine placebo group due to intercurrent illness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-13 09:07:33 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Elleg_x00e5_rd-1997">
<DESCRIPTION>
<P>All patients completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-13 09:10:18 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Scolapio-1997">
<DESCRIPTION>
<P>All patients completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-13 09:11:27 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Seguy-2003">
<DESCRIPTION>
<P>All patients completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-13 09:13:01 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Szkudlarek-2000">
<DESCRIPTION>
<P>All patients completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-04-13 12:16:35 -0400" MODIFIED_BY="John K MacDonald">
<COMPARISON ID="CMP-001" MODIFIED="2009-02-22 08:53:54 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Comparison of growth hormone with or without glutamine versus placebo</NAME>
<IV_OUTCOME CHI2="0.7509243081427258" CI_END="2.633689808322509" CI_START="0.6932078038021916" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.6634488060623502" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.4205646231440702" LOG_CI_START="-0.15913655685086023" LOG_DATA="NO" LOG_EFFECT_SIZE="0.22100943965825431" NO="1" P_CHI2="0.6869718690340318" P_Q="1.0" P_Z="7.78581956185542E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000003" Z="3.3602988766848148">
<NAME>Change in weight (Kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="3.109172268095842" CI_START="0.09082773190415816" EFFECT_SIZE="1.6" ESTIMABLE="YES" ESTIMATE="1.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="31" SE="0.77" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="41.3315426810615"/>
<IV_DATA CI_END="3.4307737087142396" CI_START="0.5692262912857604" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="32" SE="0.73" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="45.98512226609376"/>
<IV_DATA CI_END="3.374349938510675" CI_START="-2.074349938510675" EFFECT_SIZE="0.65" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33" SE="1.39" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="12.683335052844763"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.5130522059802229" CI_END="2.89800687175137" CI_START="0.9713281001634447" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.9346674859574073" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.4620994109350739" LOG_CI_START="-0.01263404710339304" LOG_DATA="NO" LOG_EFFECT_SIZE="0.28660633296059773" NO="2" P_CHI2="0.7737348090967991" P_Q="1.0" P_Z="8.278839594459408E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="3.9361814231357193">
<NAME>Change in Lean Body Mass (Kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="3.4855690267044466" CI_START="0.1144309732955533" EFFECT_SIZE="1.8" ESTIMABLE="YES" ESTIMATE="1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35" SE="0.86" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="32.66371282908578"/>
<IV_DATA CI_END="3.75037334855964" CI_START="0.8496266514403596" EFFECT_SIZE="2.3" ESTIMABLE="YES" ESTIMATE="2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="34" SE="0.74" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="44.116292929860926"/>
<IV_DATA CI_END="3.4291632642308554" CI_START="-0.5691632642308555" EFFECT_SIZE="1.43" ESTIMABLE="YES" ESTIMATE="1.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="36" SE="1.02" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="23.219994241053293"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.048308329928262" CI_END="8.58052361744069" CI_START="0.25573491782575797" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="4.418129267633224" ESTIMABLE="YES" I2="60.3827684584309" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.9335137910219489" LOG_CI_START="-0.5922099697299508" LOG_DATA="NO" LOG_EFFECT_SIZE="0.6452384185065574" NO="3" P_CHI2="0.08012613567117433" P_Q="1.0" P_Z="0.03749042170289139" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="8.084169820942334" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.080382951702784">
<NAME>Change in Energy absorption (Kcal)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="7.057125447997912" CI_START="-1.0571254479979117" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="37" SE="2.07" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="36.463069367105916"/>
<IV_DATA CI_END="16.036689072383368" CI_START="3.9633109276166323" EFFECT_SIZE="10.0" ESTIMABLE="YES" ESTIMATE="10.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38" SE="3.08" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="25.66873217452706"/>
<IV_DATA CI_END="5.833689553760346" CI_START="-1.8336895537603461" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="39" SE="1.956" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="37.868198458367026"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.868252905738453" CI_END="12.748288828317232" CI_START="-2.927488828317233" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="4.9104" ESTIMABLE="YES" I2="79.45875000000001" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.1054518943940563" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.6911168710877473" NO="4" P_CHI2="0.027355305537350993" P_Q="1.0" P_Z="0.2194814930753547" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="25.426800000000004" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.2279080962356244">
<NAME>Change in carbohydrates absorption (g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="14.291902758258146" CI_START="3.7080972417418527" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="40" SE="2.7" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="48.88"/>
<IV_DATA CI_END="5.743112842586931" CI_START="-3.743112842586931" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="41" SE="2.42" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="51.12"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.7535245844146736" CI_END="9.823317284535005" CI_START="0.20884271546499367" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="5.01608" ESTIMABLE="YES" I2="42.972" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.9922581716042788" LOG_CI_START="-0.6801806685364247" LOG_DATA="NO" LOG_EFFECT_SIZE="0.7003644543141858" NO="5" P_CHI2="0.18543437062453405" P_Q="1.0" P_Z="0.040843869037733085" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="5.3715" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999997" Z="2.0451114770638243">
<NAME>Change in fat absorption (g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="14.056288712228767" CI_START="1.9437112877712321" EFFECT_SIZE="8.0" ESTIMABLE="YES" ESTIMATE="8.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42" SE="3.09" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="40.3216"/>
<IV_DATA CI_END="7.253121846451918" CI_START="-1.2531218464519176" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="43" SE="2.17" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="59.67839999999998"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.112503555086624" CI_END="9.489187452387576" CI_START="0.20415524918840422" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="4.8466713507879895" ESTIMABLE="YES" I2="51.36782319552614" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.9772290259096443" LOG_CI_START="-0.6900394491269712" LOG_DATA="NO" LOG_EFFECT_SIZE="0.6854435715324612" NO="6" P_CHI2="0.127932874554874" P_Q="1.0" P_Z="0.040741255380422815" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="8.509695642090993" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.0461536555949817">
<NAME>Change in nitrogen absorption (g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="7.057125447997912" CI_START="-1.0571254479979117" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="44" SE="2.07" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="43.85146331079082"/>
<IV_DATA CI_END="14.037107440267938" CI_START="3.962892559732061" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="45" SE="2.57" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="37.12052605715217"/>
<IV_DATA CI_END="9.97663504919345" CI_START="-7.976635049193449" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="46" SE="4.58" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="19.02801063205701"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-04-13 05:42:15 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Comparison of Growth Hormone versus placebo</NAME>
<IV_OUTCOME CHI2="0.14212115828743999" CI_END="2.848978691732275" CI_START="0.7723394820108418" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.8106590868715584" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.4546892010479364" LOG_CI_START="-0.11219176345094262" LOG_DATA="NO" LOG_EFFECT_SIZE="0.2578366885096608" NO="1" P_CHI2="0.7061814564492641" P_Q="1.0" P_Z="6.311655631331157E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="3.417855717965073">
<NAME>Change in weight (Kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="3.109172268095842" CI_START="0.09082773190415816" EFFECT_SIZE="1.6" ESTIMABLE="YES" ESTIMATE="1.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="47" SE="0.77" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="47.3352282821105"/>
<IV_DATA CI_END="3.4307737087142396" CI_START="0.5692262912857604" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="48" SE="0.73" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="52.66477171788951"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.19422001243008064" CI_END="3.186689011639733" CI_START="0.9878914731334183" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="2.0872902423865756" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.5033396828277172" LOG_CI_START="-0.0052907631129039704" LOG_DATA="NO" LOG_EFFECT_SIZE="0.3195828428856189" NO="2" P_CHI2="0.6594273116405214" P_Q="1.0" P_Z="1.9832761343023986E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="3.7211372386187707">
<NAME>Change in Lean Body Mass (Kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="3.4855690267044466" CI_START="0.1144309732955533" EFFECT_SIZE="1.8" ESTIMABLE="YES" ESTIMATE="1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="49" SE="0.86" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="42.5419515226849"/>
<IV_DATA CI_END="3.75037334855964" CI_START="0.8496266514403596" EFFECT_SIZE="2.3" ESTIMABLE="YES" ESTIMATE="2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="50" SE="0.74" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="57.4580484773151"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.558124505311772" CI_END="12.949578581606357" CI_START="-0.6926500101777835" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="6.128464285714287" ESTIMABLE="YES" I2="71.89530612244899" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.1122556353932624" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.7873516595432257" NO="3" P_CHI2="0.059254805147359035" P_Q="1.0" P_Z="0.07824865131126243" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="17.614349999999998" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="1.7609394535103755">
<NAME>Change in energy absorption (Kcal)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="7.057125447997912" CI_START="-1.0571254479979117" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="51" SE="2.07" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="55.30765306122449"/>
<IV_DATA CI_END="16.036689072383368" CI_START="3.9633109276166323" EFFECT_SIZE="10.0" ESTIMABLE="YES" ESTIMATE="10.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="52" SE="3.08" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="44.692346938775515"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.305845837389117" CI_END="11.674336067042317" CI_START="-0.06100273370898357" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="5.806666666666667" ESTIMABLE="YES" I2="69.75055555555555" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.0672321911123337" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.7639268959519819" MODIFIED="2009-04-13 05:42:15 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.06903386514471632" P_Q="1.0" P_Z="0.05242985543393658" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="12.555100000000001" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="1.9395873830531944">
<NAME>Change in nitrogen absorption (g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="7.057125447997912" CI_START="-1.0571254479979117" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="53" SE="2.07" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="53.22222222222223"/>
<IV_DATA CI_END="14.037107440267938" CI_START="3.962892559732061" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="54" SE="2.57" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="46.77777777777778"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Studies with short durations (4 weeks or less)</NAME>
<IV_OUTCOME CHI2="0.7393509127789046" CI_END="2.974858336990931" CI_START="0.4414378090536939" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.7081480730223124" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.47346628941650737" LOG_CI_START="-0.3551304723520503" LOG_DATA="NO" LOG_EFFECT_SIZE="0.23252551536302601" NO="1" P_CHI2="0.3898689127692333" P_Q="1.0" P_Z="0.008217628533473962" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="99.99999999999999" Z="2.642994849426884">
<NAME>Change in weight (Kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="3.4307737087142396" CI_START="0.5692262912857604" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="55" SE="0.73" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="78.3813387423935"/>
<IV_DATA CI_END="3.374349938510675" CI_START="-2.074349938510675" EFFECT_SIZE="0.65" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="56" SE="1.39" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="21.61866125760649"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.4766372795969772" CI_END="3.1739563193522393" CI_START="0.8260285672976342" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.9999924433249368" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.5016009456088659" LOG_CI_START="-0.08300493281861508" LOG_DATA="NO" LOG_EFFECT_SIZE="0.30102835474974043" NO="2" P_CHI2="0.48994949088137296" P_Q="1.0" P_Z="8.406824716892859E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.3390406964941204">
<NAME>Change in Lean Body mass (Kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="3.75037334855964" CI_START="0.8496266514403596" EFFECT_SIZE="2.3" ESTIMABLE="YES" ESTIMATE="2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="57" SE="0.74" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="65.51637279596977"/>
<IV_DATA CI_END="3.4291632642308554" CI_START="-0.5691632642308555" EFFECT_SIZE="1.43" ESTIMABLE="YES" ESTIMATE="1.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="58" SE="1.02" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="34.48362720403023"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.807570962752142" CI_END="13.455353202446696" CI_START="-2.162911202446697" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="5.646221" ESTIMABLE="YES" I2="79.199475" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="1.1288951024609986" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.7517578729611143" NO="3" P_CHI2="0.02833506435868849" P_Q="1.0" P_Z="0.15645112592163676" Q="0.0" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="25.343832000000006" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.4171087800622064">
<NAME>Change in energy absorption (Kcal)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="16.036689072383368" CI_START="3.9633109276166323" EFFECT_SIZE="10.0" ESTIMABLE="YES" ESTIMATE="10.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="59" SE="3.08" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="45.5777625"/>
<IV_DATA CI_END="5.833689553760346" CI_START="-1.8336895537603461" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="60" SE="1.956" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="54.4222375"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.3204127434167354" CI_END="13.53785643612812" CI_START="-1.7414189361281203" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="5.89821875" ESTIMABLE="YES" I2="56.90421875000001" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="1.1315499042561465" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.7707208753972313" NO="4" P_CHI2="0.12768628098642576" P_Q="1.0" P_Z="0.13022897804457464" Q="0.0" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="18.209350000000008" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.5131995518491381">
<NAME>Change in nitrogen absorption (g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="14.037107440267938" CI_START="3.962892559732061" EFFECT_SIZE="9.0" ESTIMABLE="YES" ESTIMATE="9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="61" SE="2.57" STUDY_ID="STD-Seguy-2003" TOTAL_1="12" TOTAL_2="12" WEIGHT="61.227734375000004"/>
<IV_DATA CI_END="9.97663504919345" CI_START="-7.976635049193449" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="62" SE="4.58" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="8" TOTAL_2="8" WEIGHT="38.772265625"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-04-13 12:16:35 -0400" MODIFIED_BY="John K MacDonald" NO="4">
<NAME>Studies with high treatment dose</NAME>
<IV_OUTCOME CHI2="0.3574257425742575" CI_END="2.6970776342797" CI_START="0.05677979146287426" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.376928712871287" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.43089344762234727" LOG_CI_START="-1.2458062068557638" LOG_DATA="NO" LOG_EFFECT_SIZE="0.13891145630046323" NO="1" P_CHI2="0.5499396298719028" P_Q="1.0" P_Z="0.040927640287372946" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="99.99999999999999" Z="2.04426231218494">
<NAME>Change in weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="3.109172268095842" CI_START="0.09082773190415816" EFFECT_SIZE="1.6" ESTIMABLE="YES" ESTIMATE="1.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78" SE="0.77" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="1" TOTAL_2="1" WEIGHT="76.5188118811881"/>
<IV_DATA CI_END="3.374349938510675" CI_START="-2.074349938510675" EFFECT_SIZE="0.65" ESTIMABLE="YES" ESTIMATE="0.65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="79" SE="1.39" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="23.481188118811883"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.07691011235955061" CI_END="2.9349180688433067" CI_START="0.35760777385332254" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.6462629213483146" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.4675959819904816" LOG_CI_START="-0.44659304886687856" LOG_DATA="NO" LOG_EFFECT_SIZE="0.21649919671592924" NO="2" P_CHI2="0.7815292484442227" P_Q="1.0" P_Z="0.012284556701477921" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="2.503863070891068">
<NAME>Change in Lean Body Mass</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="3.4855690267044466" CI_START="0.1144309732955533" EFFECT_SIZE="1.8" ESTIMABLE="YES" ESTIMATE="1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="80" SE="0.86" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="1" TOTAL_2="1" WEIGHT="58.44943820224719"/>
<IV_DATA CI_END="3.4291632642308554" CI_START="-0.5691632642308555" EFFECT_SIZE="1.43" ESTIMABLE="YES" ESTIMATE="1.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="81" SE="1.02" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="41.550561797752806"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.08289924525211152" CI_END="5.485086628685973" CI_START="-0.8507522151202087" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="2.3171672067828823" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.7391834909924432" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.3649573736100269" NO="3" P_CHI2="0.7734062349877682" P_Q="1.0" P_Z="0.15168328995521085" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="1.4336110445395842">
<NAME>Change in Energy absorption (Kcal)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="8.625096635629955" CI_START="-2.625096635629956" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="82" SE="2.87" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="1" TOTAL_2="1" WEIGHT="31.716720678288254"/>
<IV_DATA CI_END="5.833689553760346" CI_START="-1.8336895537603461" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="83" SE="1.956" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="68.28327932171175"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.15834497828694485" CI_END="6.357810118489313" CI_START="-1.0363025159510442" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="2.6607538012691347" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.8033075531912531" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.42500469127559837" NO="4" P_CHI2="0.6906850461277914" P_Q="1.0" P_Z="0.15836945610300152" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="1.4105767331498753">
<NAME>Change in nitrogen absorption (g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MD</EFFECT_MEASURE>
<IV_DATA CI_END="7.057125447997912" CI_START="-1.0571254479979117" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84" SE="2.07" STUDY_ID="STD-Elleg_x00e5_rd-1997" TOTAL_1="1" TOTAL_2="1" WEIGHT="83.03769006345675"/>
<IV_DATA CI_END="9.97663504919345" CI_START="-7.976635049193449" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85" SE="4.58" STUDY_ID="STD-Szkudlarek-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="16.962309936543246"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-04-13 09:36:59 -0400" MODIFIED_BY="John K MacDonald">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-04-13 09:30:09 -0400" MODIFIED_BY="John K MacDonald" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAOwAAAGACAIAAAAh8BnWAAANJUlEQVR42u3dv24kVRbH8ZZICBxM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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-04-13 09:31:54 -0400" MODIFIED_BY="John K MacDonald" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Comparison of growth hormone with or without glutamine versus placebo, outcome: 1.1 Change in weight (Kg).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArsAAACgCAMAAAA7M1TBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAPnUlEQVR42u1dy67lRhX1bZ30RiiRCFFHCQTEjEk+ZTNiwMflG2BU
H8AsIwb8QQSEVqK0CI0EVLeUzjl22fUuV9nl91rpXPu43uXlXdvlZdcTNQBwSDxDFwDgLgCAuwCQ
gds5msHtXxEMEql0IpAJhzOKHl+sSaL7y9G27aHft6vkSeyuEN3/MVYnKW9mI9IJtmseH+EcrFvJ
k9hdg4tC/e02/LCt/Ngqe9pH6Q5GrbKZx7BpzCzWaI4YyCCYxU77fLNKns3fbS/+9g+3RlR0NLtv
H/3KfWB3REQ52CUesjIT6V8A7tUWYvGdrcYPl6YiN7HpioiVW7BXN3cflbydkbbc31pxoQOsvQEn
Mcws5hnWswXRWQExljCUWGx5ER7CUsBnqNafPDUwFrvd8IYEEUdgsQB35zu6ondZndsqFah/Jf1d
MyvRTVsIJ4tlWyKG60fst7u3quQTtDgA5hkAANwFAHAXAHcBANwFAHAXuDjM52q9BNMWA6Vm7WzR
5vz5vTw5qApLaHbjyYza5tY7Lx0LXX3hhvd7bs86jwC7hgWrY+Y1SNvabhI610EjV4UaO6+exd1O
38eCC1rXpVjkqhKxnHWpojRDIwUvns6vnpe2Ew1aD0vGWsVDx4ieHn5QrVOw7+rdAieqU7w2huR1
aIElkB3aM8QcoiopizCutf7oSOUz5aBipj1hJWgsyGkkXV9xDrS66cU9OafOUBtzY1vy4GjIpplf
/snWfqpn+bvqOajlBbBTJVVjYaSwBk7WibSW1o4wv/t4Xt/30l0ueU8iJ506qls99EVaLpwsMiKI
Y95aqbN19Z7ZpswvsDtZYS/FSyHGrOLoucuQg+pSeWYHiYlXQVE6kWq427WqQZ5kItT53RC5KE32
Xb2b7y8Utq1Z/WWUoVRRwXLwIul4ctN6d6m/TQr4oEbE9s6aBa/W83uq3i005pXyqPJItFqpU295
Q+lEpzjrBWfzO4Ej+YgdyHr3Ub1nUS+Sxyc2jBRs8Y5jlOQK1OJjKLI561rsb4e5Cd5XDN6R4SfZ
Tgvbgs7KnbPr6j2zvTilT+1n5YTjEDiOjpFC6LFE2BX2I4z01pgctC91or+rq1Tqt2an091kd2Dp
cOH2njF1aJ0JDp6dNXy3TauXp98tKpNFLMEhxP91ra/IbDVXirNgO3ZXvVsWc4s4J1b7fsH+kdsX
oO5idhcAAOCc+P0GZd5gd4Ea2IBH0EACRwW4CxwV2d/FkZsMC8AR8UZtn+/F7oK5wH7trlQcle2/
gOE1fpC5VTa528iZRB+K9iz9cEAVUaek8gElnU6FOq2QbddQRnuNVpJRiBvqVEHlIkkVdTmfgUrN
rtQdRv2GXJ4XEsM8p9bJ1gfIOpfzSpIxTk1MJ4OtaP+FqevH7PM1f/ihVhWkkRnJ5oLcDXq498u4
u5o7y/HowMEWRLpJ0gxbKLMuJsPOVCmpbjodhyq1N21OVC5yQ9qaSo0/BY6JNblrWAzjGtdH4l09
g1BWlonBbz51Jw+slMFFyu6WzPbm1WlLX0FkHluKuxEHkgy/iprgsCQDPvFchN3uw6FlJD1GrxFy
ZrZXVmH7yf1dmfjlcrult6zrah3xtATI1zGSxsmZ016nj89xdS/g75LnQeQNWSt0ZwWXYTErG6tV
HWcUM5VZ3DVngxzLKw/CpNXhTT5U7hRv4mWXeL4Bdy1/V3m5vkPg+QY6ZjWz8Jhrc7Mj2TRU/YxN
rXVOOrMV3T6NxrTy1U22Q9VU4SIdchxk6XdhUXfiO+edkC1O1xbC+FE9g4STtUPy5k5EXNjfBW+3
9Z0nnZTLnDFoIAFwFwB25jMAwAS8GfaWmzCD3QVOYXez5hSkq0H0ZKW1brPH9LtzS11QvxvQ3cY1
kxGFrqff9STLZhV0sZfU70pqxidmbCFpSFZai7qj+t2ZpS6o3w3pbsP63ZRC1+5Xs+V+DxnFXlu/
ayl3ZS/b7fopeJqXuNBplNk089qY9t5Fbjqq0ErX1tt7tMZpmGAOHngKHKtdv1ug/Z5Od3+oYOSX
1O8G1Ynz6mw8W04UuzEocK+23AVlcteXTeseIWPICw+VtAFD65Q6lVTph7ZWaEq/m1d80EXxMryU
oNfT7ybFjqmu3eIp+u70q5ISw/kcMT0l2y9prx2y6r1anqu5sWNQtQpVzW65frfwRpFiHsX1BFO3
sXmgYX5GJqTli/SbpIVItyB1y2c+MqOne52aRaZ6ZuD5ytzt/d2ocrfjcRtq60lpgfld6c6genLV
KqXKibPEyXSe7jaq31XZ5Op3LdYu0yHHwVO2fwAR737mUqDfTfkMjfuUDdTdE3nTI8LF/V3vjg3U
XX8SZUoQ9LsAAO4CALgLAOAucL57NXNmwbvJjT3RlK6cdKKyNyRkdQW8sU/Vzrqbn5hJJJ0j7tVS
48Czg3iTpU5uxYjpd81Q6HcnnMxZyl5PyOpTI/Gp2hnUnZhJJJ0r7tVSY1+/m2oyhWNE9LtW6HaS
sod47Pk23DW7X3XJ8OnSxjZ56ju81ifIal7tFDT8uR+13Q4hca+kyU1Oj3MUiLf8NHz4yvjj489T
k/7m4tLcpYa8784bUl77O7xexFrdE/IIjjASplQHyV6SuU7Q5o/UwiW0z9XerHuWEvpdGZLyhqRm
IU3/zGFcvRYRzU82lDACRadioe+Reb2X/P5uvMkZjLf3LnqvRqYTJUeHjCU+GK2vi5FnR0rbIitc
KDX93VSbEvpdv8lZlxQZguEdPLR/vh13bZUjRXV3jttJjVzvy7uLOlBVHV9/R05oW5EZvpjoZHx+
17OuMua41+05WVCl/VJ3ZpNHPIaMvrqIz0D9NwDUeEXt+9K2htf+Du+w/ETnZMxR9sY+NRs6nTVV
w4v4u1qV61SbyprsqXstSsfUvVfBE/RhB7Tb0O/m+QzAJuTdJOmB5xmAvYBmBEO/CwDgLgCAuwAA
7gLgLgCAuwAA7gLgLgCAuwAA7gIAuAuAuwAA7gIAuAuAuwCwY0C/CyyA9372w+u34C5wPHz2/l+b
5jcv4TMAB8P/v/j+Tt3mqw//vWw5xruW3P4d3pnTb8+xOng/wl2MNqrgx/4QrQu6x93itbsJMJoi
6qRj47gO7vvF7CsnjYom9EbF12WwX2gklAvbU6k3dZm/fv2N2vvop3/7yTp2V4juf5PJzknjR4SO
uG1s+ySooEDSXVK3ra9R7bnpOBjc74nohaDOfRuLda7C6lK/0Fjo1pbj099+03zU7b767+/+sq6/
y8qmsnCMi2eIjeutPdTti0NwV9ROxyW2yaNuehAIHRdu6C6Gu/c++Oo/d9J+9OpudV81r778/LPv
367H3QcLmQWrMY41O+3OFCUnaadOg6iZbso1K9jJNZb5SIenE6+HX75+2bx6WNzh/3+8ePHPLe7V
HiSOhHQj3KO/+BBmNtqGaunEuJvs9ZXwco1VKnh8GP9GEq+HH955h96922aewfWeFJmVV3z3ee8W
VjRADuEr9JVjS3h/ff9SfvLwdY3/f/HlYlNltxLq6jkGYCsnnfdM3aZ5+6+Pn77r3IWHv/vig68/
X2OeIcfVY/vq145t50MciNdT61qUzowcvwkYyVIHW92vqOuEbo9v//yxmmVoml/97+sFS7K+pce9
x99d4GKYxxV95+ubgm5rTP8M87vHuVVbfH6XjUlaDk6VsR1ryJWDmfBwZobpeD8xbzy/27z34d/b
7Ysv/rBomQXfgcztE4YLXOPKmjyPszl376x6/7ulH0yU+QyiekRgxL5Po+72ePflp5/8/NuFqYvv
7wIL2N11AC0OcFSAuwC4CwDgLgDgXg2YuuzhXtOYiWB3gaPCX9dyxurAgUVHpV7ptenXdgxH0QvI
u3HsheSdROG10+0ofSWcNc9StZENXW2ZyENzdzYoaOENBlBD3hpKOgoZ/B0ZXox81RrSiSjWuvNk
xovWpv0H6h6Ru1Ktb0lNv3TisPuwSGpR4S5Am7T2lxzi93zqV71UrBhd/Vw6Szu2hTk8onmXlbzO
8ufyZGnGuKstVM8lvduR2AkYKEf9is/k8KZ3J6S5nDaFzau5wKi6ZoyV5ZOLQ8fyNQ498tLUTdTm
HGb3dPdqEe7KvB4wFyT3i6fgYEv2dmxxO2tgl2nb2RgeMqX9cBmuVagRTT+GAIfwGYbzm7FCuKxp
/edaiqxlII1lvPNyDNx6Arv3d2mcFQX+Z4AAk0ZpK1E4rkzVhrIytmchgAPOMySmymTY1STDoTR3
QyyjAqrLUKIIzansEppu6U/s7u46jZkoyF0aZmVJ3zepXTXykrSss3TtoSQ3IFoZ6Xi41oHIQC+H
G7roTJbORte8odBURqjpKt1ZWO3fBI8NcGUtlxOYWFBKuPpPM5/LVbt/nJxLaWnygg8d5DADntXy
KQ+lpiWaVf3iZ8LyjjWomz+IyIV67ETUpR12UQF1qdDfne6kVGo5VY+oY1+Mv8UWcZUeyi6Fmkrc
BS7B9RVs7+xSwN2ze7pFJlQqzclOZ0DAXbgLS/t76wD6XSBgfA9RijFHJoOXXj9fWzb0kK8Gc3Iw
pFyhUoPa2z5liV43qt694ExDwfwuFRNxyvwuzar+E43MRriC9EncDYnSU0/JItpbK6/cNP4GOAdC
PoOUcthIpc2R/WGpDKUKbZwQldbO6x5iBvb5yuglE9RTgHXA2L1a4DUDR8rb2A85fJGvkxdZKt/2
n6miTTkPptcR4LksZTVehjg1d0duO8lmgvVGTy6LgkpcClHVeCAobde88CEDSVjuC3BXlp5sGb97
lOO3ljJ8hUgy92a+8nNNGcMFuavfJpClD+2k+/Yi5VNOTqClnErl66H7lnJxKlFyuLSQYDac+/XW
W95Ewaj7aMh9k3bVn7aQ5DM7+z17sDYf4jSFxOcZqFOKqc3ARbIEZOYvY58ckZmVSGdMesJCtso0
GayC9CqTkI3F0tgbuA3tYkPc2chu4aH+hz7SHtArM6hFAtj44fyaVgir/3QJPBxkuwh1xPq68C1g
xsj/QW6gFYmsXTLv2si8i3PSJO623FJzfI9YmpzXOy9EXWEs6CisUZiFeYT7xRfUseGffSA4xGcW
InROejMcbPwC7fV+j/dMeNZrZFc2u8x6jQzBAc6J0Ca4sGncNygsJJW9GHNGDqjFoY3SnsTfTX7T
X4SWxuToj1qFcCIVF80zAGf3GZLcc22lnUIsUYhIpBIl92rABWbLbM/RWBw+aO/Y23CdQtxAbgpM
L+zu1TwH1gtwq8HbOGQM5/2yen1w97uPYP+aXEhHbieKxXinCDMM344GosP+zgGfATgqYHeBowJ2
FwB3AQDcBQBwFwB3AQDcBQBwFwB3AeCY+BFot/OiCEqIuQAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-04-13 09:33:30 -0400" MODIFIED_BY="John K MacDonald" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Comparison of growth hormone with or without glutamine versus placebo, outcome: 1.2 Change in Lean Body Mass (Kg).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArsAAACgCAMAAAA7M1TBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-04-13 09:34:15 -0400" MODIFIED_BY="John K MacDonald" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Comparison of growth hormone with or without glutamine versus placebo, outcome: 1.3 Change in Energy absorption (Kcal).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAswAAACgCAMAAAAvpsogAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-04-13 09:36:59 -0400" MODIFIED_BY="John K MacDonald" NO="5" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Comparison of growth hormone with or without glutamine versus placebo, outcome: 1.5 Change in fat absorption (g).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsUAAACQCAMAAADXyeZHAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>